New tools in gastrointestinal bleeding (GIB) management, including hemostatic powders, capsule endoscopy, endoscopic clips, and over-the-scope devices, offer targeted approaches for various GIB cases. Hemostatic powders like Hemospray aid in rapid clotting, while capsule endoscopy enables less invasive detection of small intestine bleeds. Endoscopic clips, bands, and over-the-scope clips manage challenging bleeds, while suturing and thermal coagulation provide precision control. Together, these advancements significantly enhance GIB treatment options.
Author: Rutali Thakur
At the American College of Gastroenterology Meeting, Eli Lilly and Johnson & Johnson presented Phase III results showing high remission rates for their Crohn’s disease drugs, Omvoh and Tremfya. J&J’s Tremfya achieved up to 66% remission at 48 weeks, offering options for subcutaneous and intravenous administration. Lilly’s Omvoh demonstrated a 96% response rate, with 87% of patients reaching remission, also showing efficacy in ulcerative colitis. Both companies are seeking approval for expanded use in Crohn’s, aiming to set new treatment standards.
With anticipation running high in the healthcare sector over upcoming election outcomes, potential shifts in healthcare policy could influence how care is delivered and funded, ultimately affecting investment dynamics in both public and private markets. In a four-part series examining these implications, policy expert Julie Barnes set the stage by discussing possible policy directions under different election results. In Part 2, Richard Close, Managing Director of Digital and Tech-Enabled Health Equity Research at Canaccord Genuity, joins Keith Figlioli to explore how these potential changes might shape healthcare investing.
The Healio Disruptive Innovator Awards, held at the American College of Gastroenterology’s Annual Meeting, spotlighted leading-edge advancements across gastroenterology and hepatology. With nine award categories, the event honored innovators who significantly impact patient care, research, and professional collaboration within the field. These awardees, selected by over 3,500 votes from Healio’s readership, include physicians, researchers, and industry leaders who push boundaries in areas like clinical innovation, health equity, and technology, aiming to transform and elevate gastroenterology practice. Notably, the ceremony introduced Healio Community, a new clinician wellness platform designed for networking, mentorship, and job opportunities, further underscoring Healio’s commitment to supporting…
US Digestive Health (USDH) has added seven physicians to its growing team, reinforcing its commitment to delivering top-tier GI care. These specialists will practice across multiple counties in Pennsylvania, including Berks, Lancaster, and Montgomery, enhancing access to gastroenterology services. With 40 locations, 24 surgery centers, and over 250 GI providers, USDH is one of the nation’s largest GI practices.
In this episode of The Interventional Endoscopist Podcast, you’ll join Dr. Doug Adler, Director of the Center for Advanced Therapeutic Endoscopy at Porter Adventist Hospital, as he shares his experience transitioning from a 20-year academic career to a hybrid practice model. This blend of private practice and academic responsibilities is becoming a popular path among interventional endoscopists. Dr. Adler takes you through his journey, from medical training at Cornell and the Mayo Clinic to becoming a leader in therapeutic endoscopy. He also reflects on the mentors who shaped his career, his passion for procedural medicine, and cutting-edge techniques like endoscopic…
Physicians face evolving challenges in malpractice insurance, with trends shaped by market dynamics and legal shifts. Experts Brad Ash and Wayne de Nazarie from ISMIE Mutual Insurance Co. suggest that physicians should prioritize financial strength and geographic reach when selecting medical professional liability (MPL) carriers. The MPL market, characterized as “hardening” since 2019, reflects increased stability but remains competitive. The rise of hospital acquisitions and private equity in healthcare brings pros like financial stability and reduced administrative burdens but also cons like contractual conflicts and adjustment challenges. Additionally, large malpractice verdicts have surged, driven by plaintiff strategies like anchoring, which…
In a surprise move, Nobel laureates Emmanuelle Charpentier and Jennifer Doudna are seeking to cancel two of their own key CRISPR patents in Europe. This decision follows a ruling that their initial patent application lacked enough detail for replication. The move aims to avoid a damaging legal precedent. The situation affects a broad network of biotech companies involved in CRISPR licensing and further complicates the ongoing CRISPR patent dispute between their team and the Broad Institute.
Geneoscopy, Inc. has received a New York State Department of Health laboratory permit, allowing it to offer services across all 50 states. Its first commercial test, ColoSense™, is a noninvasive RNA-based stool screening test for colorectal cancer and advanced adenomas. The approval underscores Geneoscopy’s high-quality standards, meeting the rigorous requirements of the Clinical Laboratory Evaluation Program (CLEP). The company aims to improve early detection of colorectal cancer by providing a reliable and accessible testing option to patients nationwide.
The American Gastroenterological Association’s new guideline on Barrett’s esophagus focuses on updates for endoscopic eradication therapy (EET). Key highlights include management of low-grade dysplasia, the use of endoscopic resection techniques, and the need for expert consultations. The guideline emphasizes the importance of shared decision-making between doctors and patients, weighing risks and benefits of EET. GEN’s Sarah Tilyou spoke with Joel H. Rubenstein, MD, a research scientist at the Veterans Affairs Center for Clinical Management Research and professor of gastroenterology and the director of the Barrett’s Esophagus Program at the University of Michigan, in Ann Arbor, about the guideline and its…